Adversity is less terrifying than hope: Vanda Pharmaceuticals Inc (VNDA)

With 0.57 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.66 million shares. The 52-week range on VNDA shows that it touched its highest point at $6.75 and its lowest point at $3.85 during that stretch. It currently has a 1-year price target of $12.67. Beta for the stock currently stands at 0.69.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VNDA was down-trending over the past week, with a drop of -2.88%, but this was up by 4.53% over a month. Three-month performance dropped to -3.31% while six-month performance fell -6.01%. The stock lost -10.25% in the past year, while it has lost -8.56% so far this year. A look at the trailing 12-month EPS for VNDA yields -0.33 with Next year EPS estimates of -0.14. For the next quarter, that number is -0.26. This implies an EPS growth rate of -265.66% for this year and 88.12% for next year.

Float and Shares Shorts:

At present, 58.31 million VNDA shares are outstanding with a float of 54.97 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VNDA since 2 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.20781 being high and -$0.37605 being low. For VNDA, this leads to a yearly average estimate of -$0.31667.